FY2026 EPS Estimates for McKesson Lifted by Leerink Partnrs

McKesson Co. (NYSE:MCK - Free Report) - Leerink Partnrs increased their FY2026 earnings per share estimates for McKesson in a research note issued on Thursday, November 7th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $37.21 for the year, up from their prior forecast of $35.93. The consensus estimate for McKesson's current full-year earnings is $32.81 per share. Leerink Partnrs also issued estimates for McKesson's FY2027 earnings at $41.97 EPS.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.88 by $0.19. The company had revenue of $93.65 billion for the quarter, compared to analysts' expectations of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. McKesson's quarterly revenue was up 21.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.23 earnings per share.

Several other brokerages also recently commented on MCK. Evercore ISI increased their price objective on shares of McKesson from $560.00 to $680.00 and gave the company an "outperform" rating in a research report on Thursday. Leerink Partners cut their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. Robert W. Baird upgraded shares of McKesson from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $531.00 to $688.00 in a report on Thursday. Citigroup cut their target price on McKesson from $670.00 to $630.00 and set a "buy" rating on the stock in a research note on Tuesday, September 10th. Finally, Barclays boosted their price target on McKesson from $596.00 to $616.00 and gave the stock an "overweight" rating in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, McKesson presently has an average rating of "Moderate Buy" and a consensus price target of $625.64.

McKesson Stock Up 0.4 %

Shares of NYSE:MCK traded up $2.59 during midday trading on Monday, reaching $615.59. The company's stock had a trading volume of 1,103,396 shares, compared to its average volume of 824,293. McKesson has a 12-month low of $431.35 and a 12-month high of $637.51. The firm has a market capitalization of $79.83 billion, a P/E ratio of 31.75, a PEG ratio of 1.39 and a beta of 0.44. The firm has a 50 day moving average of $513.03 and a 200-day moving average of $551.85.

Institutional Investors Weigh In On McKesson

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in McKesson by 1.1% in the 1st quarter. JPMorgan Chase & Co. now owns 4,362,837 shares of the company's stock worth $2,342,190,000 after purchasing an additional 46,659 shares during the period. Legal & General Group Plc raised its position in shares of McKesson by 2.9% during the 2nd quarter. Legal & General Group Plc now owns 1,297,620 shares of the company's stock worth $757,862,000 after purchasing an additional 36,583 shares during the last quarter. Swedbank AB acquired a new position in shares of McKesson during the first quarter valued at approximately $669,326,000. Boston Partners raised its holdings in shares of McKesson by 4.1% during the first quarter. Boston Partners now owns 1,183,829 shares of the company's stock valued at $635,763,000 after acquiring an additional 47,140 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of McKesson by 7.9% in the second quarter. AQR Capital Management LLC now owns 857,611 shares of the company's stock valued at $500,879,000 after acquiring an additional 62,875 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company's stock.

Insider Activity

In other McKesson news, CEO Brian S. Tyler sold 3,753 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total transaction of $2,105,808.30. Following the sale, the chief executive officer now directly owns 78,586 shares of the company's stock, valued at approximately $44,094,604.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.11% of the company's stock.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date is Monday, December 2nd. McKesson's dividend payout ratio is presently 14.71%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.